Cerevel Therapeutics Holdings Inc expected to post a loss of 61 cents a share - Earnings Preview

Reuters07-29

* Cerevel Therapeutics Holdings Inc is expected to show no change in quarterly revenue when it reports results on July 31 (estimated) for the period ending June 30 2024

*

* LSEG's mean analyst estimate for Cerevel Therapeutics Holdings Inc is for a loss of 61 cents per share.

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Cerevel Therapeutics Holdings Inc is $45.00, above its last closing price of $44.62.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Mar. 31 2024 -0.67 -0.61 -0.73 Missed -19.4

Dec. 31 2024 -0.59 -0.59 -0.76 Missed -27.8

Sep. 30 2023 -0.64 -0.63 -0.61 Beat 3.5

Jun. 30 2023 -0.64 -0.65 -0.63 Beat 2.9

Mar. -0.69 -0.67 -0.67 Met 0.6

31 2023

Dec. 31 2022 -0.64 -0.64 -0.59 Beat 8

Sep. 30 2022 -0.62 -0.62 -0.66 Missed -7.1

Jun. 30 2022 -0.50 -0.48 -0.62 Missed -30.3

This summary was machine generated July 29 at 15:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2455979660?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-29 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2455979660","market":"us","top_or_hot":-1,"title":"Cerevel Therapeutics Holdings Inc    expected to post a loss of 61 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* Cerevel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Inc     is expected to show no change in quarterly revenue when it reports  results on July 31 (estimated) for the period ending June 30 2024</p><p>   * </p><p>   * LSEG's mean analyst estimate for Cerevel Therapeutics Holdings Inc is for a loss of 61 cents per share. </p><p>   * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy,\" 9 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Cerevel Therapeutics Holdings Inc is $45.00, above its last closing price of $44.62. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Mar. 31 2024  -0.67       -0.61      -0.73     Missed  -19.4</p><p>Dec. 31 2024  -0.59       -0.59      -0.76     Missed  -27.8</p><p>Sep. 30 2023  -0.64       -0.63      -0.61     Beat    3.5</p><p>Jun. 30 2023  -0.64       -0.65      -0.63     Beat    2.9</p><p>Mar.        -0.69       -0.67      -0.67     Met     0.6</p><p>31 2023                                                </p><p>Dec. 31 2022  -0.64       -0.64      -0.59     Beat    8</p><p>Sep. 30 2022  -0.62       -0.62      -0.66     Missed  -7.1</p><p>Jun. 30 2022  -0.50       -0.48      -0.62     Missed  -30.3</p><p>This summary was machine generated July 29 at 15:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cerevel Therapeutics Holdings Inc    expected to post a loss of 61 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCerevel Therapeutics Holdings Inc    expected to post a loss of 61 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-29 23:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Cerevel Therapeutics Holdings Inc     is expected to show no change in quarterly revenue when it reports  results on July 31 (estimated) for the period ending June 30 2024   *    * LSEG's mean ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2455979660","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2455979660","pubTimestamp":1722268544,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Cerevel Therapeutics Holdings Inc     is expected to show no change in quarterly revenue when it reports  results on July 31 (estimated) for the period ending June 30 2024   *    * LSEG's mean analy","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","CERE":"Cerevel Therapeutics Holdings, Inc."},"translate_title":"Cerevel Therapeutics Holdings Inc预计每股亏损61美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CERE":0.9},"content_text":"* Cerevel Therapeutics Holdings Inc     is expected to show no change in quarterly revenue when it reports  results on July 31 (estimated) for the period ending June 30 2024   *    * LSEG's mean analyst estimate for Cerevel Therapeutics Holdings Inc is for a loss of 61 cents per share.    * The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy,\" 9 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Cerevel Therapeutics Holdings Inc is $45.00, above its last closing price of $44.62. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Mar. 31 2024  -0.67       -0.61      -0.73     Missed  -19.4Dec. 31 2024  -0.59       -0.59      -0.76     Missed  -27.8Sep. 30 2023  -0.64       -0.63      -0.61     Beat    3.5Jun. 30 2023  -0.64       -0.65      -0.63     Beat    2.9Mar.        -0.69       -0.67      -0.67     Met     0.631 2023                                                Dec. 31 2022  -0.64       -0.64      -0.59     Beat    8Sep. 30 2022  -0.62       -0.62      -0.66     Missed  -7.1Jun. 30 2022  -0.50       -0.48      -0.62     Missed  -30.3This summary was machine generated July 29 at 15:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455979660"}